SK Bioscience Co Ltd 302440
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 302440 is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- KRW 60,100.00
- Day Range
- KRW 59,200.00–60,100.00
- 52-Week Range
- KRW 56,700.00–88,600.00
- Bid/Ask
- KRW 59,700.00 / KRW 59,900.00
- Market Cap
- KRW 4.57 Tril
- Volume/Avg
- 41,670 / 74,075
Key Statistics
- Price/Earnings (Normalized)
- 427.06
- Price/Sales
- 12.40
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
SK Bioscience Co Ltd is a South Korean pharmaceutical company. It is engaged in the manufacturing and developing of vaccine. The company has registered SKYCellflu prefilled syringe (PFS), the first cell culture influenza vaccine in Korea, followed by the licensure of SKYCellflu Quadrivalent prefilled syringe and 13-valent Pneumococcal Conjugate Vaccine. Further it has several other vaccines under development and clinical trials including recombinant rotavirus vaccine. In addition, the development of new typhoid conjugate vaccine and innovative pneumococcal vaccine is ongoing in collaboration with external partners.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Core
- Total Number of Employees
- 1,122
- Website
- https://www.skbioscience.co.kr
Comparables
Valuation
|
Metric
|
302440
|
011000
|
182400
|
|---|---|---|---|
Price/Earnings (Normalized) | 427.06 | — | 3.51 |
Price/Book Value | 2.70 | 1.67 | 1.33 |
Price/Sales | 12.40 | 4.59 | 15.09 |
Price/Cash Flow | 95.99 | — | — |
Price/Earnings
302440
011000
182400
Financial Strength
|
Metric
|
302440
|
011000
|
182400
|
|---|---|---|---|
Quick Ratio | 9.56 | — | — |
Current Ratio | 10.20 | 1.62 | 0.27 |
Interest Coverage | −3.45 | −65.27 | −30.04 |
Quick Ratio
302440
011000
182400
Profitability
|
Metric
|
302440
|
011000
|
182400
|
|---|---|---|---|
Return on Assets (Normalized) | 2.49% | −27.13% | 3.12% |
Return on Equity (Normalized) | 2.86% | −38.17% | 7.44% |
Return on Invested Capital (Normalized) | 2.26% | −30.62% | 4.32% |
Return on Assets
302440
011000
182400
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dqtrynpzdt | Txsr | $586.1 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fmvbmpdnh | Yvyxwb | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cpyqzpvn | Skcmz | $108.2 Bil | |
MRNA
| Moderna Inc | Dkgbpjqbw | Pvp | $50.9 Bil | |
ARGX
| argenx SE ADR | Fjtwcpxvc | Xjjzx | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Srxwnxqx | Rnvqm | $21.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Vkmqxnz | Nwfxrhr | $18.9 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mjjhlnlp | Hrgfby | $14.6 Bil | |
INCY
| Incyte Corp | Ktgtkwwrw | Sdczbz | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Txsjpbmzw | Tjdhjp | $12.3 Bil |